Bunge Global (NYSE:BG) Stock

Bunge Global

Bunge

Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.

Bunge Global SA

BIONEUTRA GLOBAL CORP by BioNeutra Global Corporation

BioNeutra Global Corp

Pace Metals Ltd

PROXIMUS SA DE DROIT PUB by Proximus Group

Proximus SA

PROXIMUS GROUP UNSP/ADR by Proximus Group

BRAVADA GOLD CORP NEW by Bravada Gold Corp.

Bravada Gold Corp

Blackstone Strategic Credit 2027 Term Fund Common Shares of Beneficial Interest

Blackstone Strategic Credit Fund

Bitget Token - United States Dollar

BGC Group Inc

BAILLIE GIFFORD CH GRTH by BAILLIE GIFFORD CHINA GROWTH TR PLC

BEGA CHEESE LTD UNSP/ADR by Bega Cheese Ltd

Bega Cheese Ltd

BARTON GOLD HLDGS LTD by Barton Gold Holdings Limited

Barton Gold Holdings Ltd

ETF Series Solutions Bahl & Gaynor Dividend ETF

BLUE GEM ENTERPRISE by Blue Gem Enterprise

Blue Gem Enterprise

BEAUCE GOLD FIELDS INC by BEAUCE GOLD FIELDS INC.

Beauce Gold Fields Inc

BESTGOFER INC by BESTGOFER INC.

Big 5 Sporting Goods Corporation - Common Stock

Big 5 Sporting Goods Corp

BILL IDENTITY LTD by BILL IDENTITY LTD

Barings Global Short Duration High Yield Fund Common Shares of Beneficial Interests

Barings Global Short Duration High Yield Fund

Birks Group Inc

ETF Series Solutions Bahl & Gaynor Income Growth ETF

BGI INC by BGI, Inc.

BAILLIE GIFFORD JAPAN TR by Baillie Gifford Japan Trust Plc. (The)

BANGKOK BK PLC UTS by Bangkok Bank Public Co Ltd.

Bangkok Bank PCL

BioGaia AB

BioNexus Gene Lab Corp

FT Vest Gold Strategy Quarterly Buffer ETF

BEAGLEE INC by BEAGLEE INC.

BLACKSTONE LN FING NEW by BLACKSTONE LN FINANCING LTD

BGM Group Ltd

BG Medicine Inc

BERGAMO AQUISITION CORP by Bergamo Acquisition Corp.

Banca Generali

Blackgold Natural Resources PLC

BIO-GENEX LABS INC by BIO-Genex Laboratories Inc.

Bango PLC

BANG & OULFSEN B ORD by Bang & Olufsen AS

Bang & Olufsen AS

CRAFT 1861 Global Holdings Inc Warrants (01/05/2026)

CRAFT 1861 Global Holdings Inc

BTS Group AB

CRAFT 1861 GLBL HLDGS INC by CRAFT 1861 Global Holdings Inc.

BlackRock Energy & Resources Trust

TONY G CO-INVT HLDGS LTD by TONY G CO-INVT HLDGS LTD.

Tony G Co-Investment Holdings Ltd

iShares USD Green Bond ETF

iShares Large Cap Growth Active ETF

BLUESTEM GROUP INC by Bluestem Group Inc.

Bluestem Group Inc

B&G Foods Inc

BGSF Inc

SHIN NIPPON PLC BAILLE by Shin Nippon Plc Baille Gifford

Build Acquisition Corp Warrants (01/01/9999)

Blackrock Floating Rate Income Trust

BIGtoken Inc

GOAT Industries Ltd

Benguet Corp

Blackstone Long Short Credit Income Fund Common Shares

Blackstone Long-Short Credit Income Fund

BGX - BLACK GOLD EXPL CRP by BGX - BLACK GOLD EXPLORATION CORP.

Bright Green Corp

BRIGHT GREEN CORP by Bright Green Corporation

Blackrock Enhanced International Dividend Trust

<a href="https://www.bloomberg.com/news/articles/2025-06-13/bunge-s-viterra-deal-cleared-by-china-paving-way-for-closing" title="https://www.bloomberg.com/news/articles/2025-06-13/bunge-s-viterra-deal-cleared-by-china-paving-way-for-closing">https://www.bloomberg.com/news/articles/2025-06-13/bunge-s-viterra-deal-cleared-by-china-paving-way-for-closing</a>

News

Global

'Bunge's Viterra Deal Cleared by China, Paving Way for Closing' - Bloomberg News

<a href="https://www.bloomberg.com/news/articles/2025-06-12/bunge-close-to-getting-china-ruling-on-8-2-billion-viterra-deal" title="https://www.bloomberg.com/news/articles/2025-06-12/bunge-close-to-getting-china-ruling-on-8-2-billion-viterra-deal">https://www.bloomberg.com/news/articles/2025-06-12/bunge-close-to-getting-china-ruling-on-8-2-billion-viterra-deal</a>

Reported June 12, 2025: 'Bunge Nears China Ruling For $8.2 Billion Viterra Merger' - Bloomberg News

U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday.
Shares of Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) rose sharply during Friday's session after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million. The company also announced termination of definitive<a href="https://www.benzinga.com/quote/UMAC"> agreement to acquire Aloft.</a>
Unusual Machines shares jumped 19.5% to $9.85 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares jumped 22.8% to $217.17 after the company reported better-than-expected first-quarter adjusted EPS results and announced it is maintaining its current FY25 guidance despite tariff and macroeconomic event uncertainty.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) gained 18.3% to $10.40.</li>
<li>Columbus Circle Capital Corp I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCM#NASDAQ">CCCM</a>) rose 13.5% to $11.95.</li>
<li>Darling Ingredients Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) surged 11.4% to $35.08.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) rose 11.1% to $3.00.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 10.8% to $5.38.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) climbed 9.9% to $22.36 as the company announced 76-week results from Barzolvolimab Phase 2 study in chronic spontaneous urticaria at EAACI Congress 2025.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) rose 8.4% to $12.01. UroGen Pharma shares traded higher on Thursday after the FDA approved ZUSDURI for intravesical solution as the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.</li>
<li>DoubleDown Interactive Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) gained 6.9% to $8.71. DoubleDown Interactive recently announced the pricing of its secondary offering of 4,347,827 ADS by selling shareholders at $8.50 per ADS.</li>
<li>Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) gained 6.7% to $2.2309.</li>
<li>Phathom Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) gained 5.5% to $10.58.</li>
<li>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) rose 5% to $80.89.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

ANNA

CCCM

CLDX

Highest Performances Holdings Inc. - American Depository Shares

MAAS

PHAT

UMAC

URGN

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday

Ratings for Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $80.75, a high estimate of $87.00, and a low estimate of $74.00. A decline of 10.53% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746730853_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Bunge Global among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pooran Sharma</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$74.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bunge Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bunge Global compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Bunge Global's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bunge Global's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bunge Global analyst ratings.</a>
<h2>Unveiling the Story Behind Bunge Global</h2>
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
<h3>Bunge Global's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Bunge Global's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -9.33% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Bunge Global's net margin is impressive, surpassing industry averages. With a net margin of 4.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bunge Global's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.4%, the company showcases effective utilization of assets.
Debt Management: Bunge Global's debt-to-equity ratio surpasses industry norms, standing at 0.72. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Bunge Global Through The Eyes Of 4 Analysts

Stephens &amp; Co. analyst Pooran Sharma maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Overweight and lowers the price target from $90 to $85.

Price Target

Stephens & Co. Maintains Overweight on Bunge Global, Lowers Price Target to $85

Bunge Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) shares are trading higher in the premarket session on Wednesday<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45246792/bunge-reports-first-quarter-2025-results" rel="noreferrer noopener"> after reporting first-quarter results</a>.
The company reported quarterly adjusted earnings per share of $1.81, beating the street view of $1.29. Quarterly sales of $11.64 billion (down 13% year over year) missed the analyst consensus estimate of $13.05 billion.
&#8220;We benefited in the first quarter from tariff-related timing shifts in demand and farmer activity and remain confident in our ability to continue to execute despite the current market environment,&#8221; said Greg Heckman, Bunge&#8217;s Chief Executive Officer.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44990627/bunge-repsol-launch-next-gen-biofuel-initiative-in-europe-target-90-emissions-cut" rel="noreferrer noopener">Bunge, Repsol Launch Next-Gen Biofuel Initiative In Europe, Target 90% Emissions Cut</a>
Adjusted Segment EBIT in the quarter under review was $406 million, lower than $719 million in the year-ago period.&nbsp;
Gross profit was&nbsp;$597 million, lower than $876 million in the year-ago period.
The company exited the quarter with cash and equivalents worth $3.245 billion, and inventories worth $7.817 billion.
Bunge&#8217;s long-term debt at quarter end was $4.714 billion, higher than $4.694 billion at the end of December 31, 2024.
Bunge is in the final stage of the regulatory process for its Viterra transaction. It has also strengthened business alignment by agreeing to divest its regional corn milling and margarine businesses.
Outlook: Bunge has maintained its 2025 adjusted earnings per share forecast at approximately $7.75, slightly below the $7.79 estimate, excluding the impact of upcoming acquisitions and divestitures.
Bunge expects its 2025 adjusted effective tax rate to range between 21% and 25%.
Capital expenditures are expected to fall within the $1.5 billion to $1.7 billion range. Depreciation and amortization are forecast at approximately $490 million.
Price Action: Bunge shares are trading higher by 0.03% to $78.19 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45205432/opec-just-created-the-income-trade-of-the-decade" target="_blank" rel="noreferrer noopener">OPEC Just Created The Income Trade Of The Decade</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Guidance

General

Bunge Q1 EPS Beats Expectations, CEO Credits 'Tariff-Related Timing Shifts' As Tailwind

<ul>
<li>Outlook(5)</li>
</ul>
Taking into account first quarter results, the current margin and macro environment and forward curves, we continue to forecast full-year 2025 adjusted EPS of approximately $7.75. This forecast excludes the impact of announced acquisitions and divestitures that are expected to close during the year.
In Agribusiness, full-year results are forecasted to be slightly lower than our previous outlook and down from last year primarily due to lower results in Processing.
In Refined and Specialty Oils, full-year results are expected to be similar to our previous outlook and down from the prior year primarily driven by a more balanced supply and demand environment in North America.
In Milling, full-year results are expected to be similar to our previous outlook and up from last year.
In Corporate and Other, full-year results are expected to be more favorable than our previous outlook and the prior year.
Additionally, the Company expects the following for 2025: an adjusted annual effective tax rate in the range of 21% to 25%; net interest expense in the range of $220 to $250 million, which is down from our previous expected range of $250 to $280 million; capital expenditures in the range of $1.5 to $1.7 billion; and depreciation and amortization of approximately $490 million.

Bunge Global Maintains Its 2025 Adjusted EPS Forecast At Around $7.75,  Vs $7.79 Est.; Excluding Upcoming Acquisitions And Divestitures

Bunge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.29 by 40.31 percent. This is a 40.46 percent decrease over earnings of $3.04 per share from the same period last year. The company reported quarterly sales of $11.64 billion which missed the analyst consensus estimate of $13.05 billion by 10.81 percent. This is a 13.22 percent decrease over sales of $13.42 billion the same period last year.

Earnings Beats

Earnings Misses

Bunge Q1 Adj. EPS $1.81 Beats $1.29 Estimate, Sales $11.64B Miss $13.05B Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/BG/earnings">opening bell on Wednesday</a>.
Analysts expect the company to report quarterly earnings at $1.30 per share, down from $3.04 per share in the year-ago period. Bunge projects quarterly revenue of $13.18 billion, compared to $13.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 24, Bunge along with Repsol (OTC:<a class="ticker" href="https://www.benzinga.com/stock/REPYY#OTC">REPYY</a>) disclosed a significant advancement in Europe's renewable energy sector. The company introduced camelina and safflower, classified as intermediate novel crops, into the renewable fuel production process.
With the recent buzz around Bunge, some investors may be eyeing potential gains from the company's dividends too. As of now, Bunge offers an annual dividend yield of 3.50%, which is a quarterly dividend amount of 68 cents per share ($2.72 a year).
To figure out how to earn $500 monthly from Bunge, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Bunge's $2.72 dividend: $6,000 / $2.72 = 2,206 shares.
So, an investor would need to own approximately $171,671 worth of Bunge, or 2,206 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $2.72 = 441 shares, or $34,319 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
BG Price Action: Shares of Bunge fell by 1.8% to close at $77.82 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a></li>
</ul>
Photo: Shutterstock

Long Ideas

REPYY

How To Earn $500 A Month From Bunge Global Stock Ahead Of Q1 Earnings

<a href="https://www.bloomberg.com/news/articles/2025-05-02/us-china-tensions-said-to-stall-8-2-billion-bunge-viterra-deal" title="https://www.bloomberg.com/news/articles/2025-05-02/us-china-tensions-said-to-stall-8-2-billion-bunge-viterra-deal">https://www.bloomberg.com/news/articles/2025-05-02/us-china-tensions-said-to-stall-8-2-billion-bunge-viterra-deal</a>

Politics

'US-China Tensions Stall Bunge's $8.2B Viterra Deal' - Bloomberg News

Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) ("Bunge"), today announced that its wholly-owned subsidiary, Bunge Limited Finance Corp. ("BLFC"), has further extended the expiration date of its previously announced (A) offers to exchange (each an "Exchange Offer" and, collectively the "Exchange Offers") any and all outstanding 2.000% Notes due 2026 (the "Existing Viterra 2026 Notes"), 4.900% Notes due 2027 (the "Existing Viterra 2027 Notes"), 3.200% Notes due 2031 (the "Existing Viterra 2031 Notes") and 5.250% Notes due 2032 (the "Existing Viterra 2032 Notes", and together with the Existing Viterra 2026 Notes, the Existing Viterra 2027 Notes, and the Existing Viterra 2031 Notes, collectively, the "Existing Viterra Notes"), each series as issued by Viterra Finance B.V. ("VFBV") and guaranteed by Viterra Limited ("Viterra") and Viterra B.V., for (1) up to $1.95 billion aggregate principal amount of new notes to be issued by BLFC and guaranteed by Bunge (the "New Bunge Notes"), and (2) cash; and (B) related solicitations of consents by BLFC, on behalf of VFBV (each a "Consent Solicitation" and, collectively, the "Consent Solicitations") from Eligible Holders (as defined below) of the (1) Existing Viterra 2026 Notes and the Existing Viterra 2031 Notes to amend the VFBV base indenture dated April 21, 2021, governing the Existing Viterra 2026 Notes and the Existing Viterra 2031 Notes (the "Existing Viterra 2026 and 2031 Notes Indenture"); and (2) Existing Viterra 2027 Notes and the Existing Viterra 2032 Notes to amend the VFBV base indenture dated April 21, 2022, governing the Existing Viterra 2027 Notes and the Existing Viterra 2032 Notes (the "Existing Viterra 2027 and 2032 Notes Indenture", and with the Existing Viterra 2026 and 2031 Notes Indenture, each an "Existing Viterra Indenture" and collectively, the "Existing Viterra Indentures"). Bunge and BLFC hereby extend such expiration date from 5:00 p.m., New York City time, on May 5, 2025, to 5:00 p.m., New York City time, on June 13, 2025, unless further extended (the "Expiration Date").
On the early tender date and consent revocation deadline of September 20, 2024, BLFC received consents sufficient to amend the respective Existing Viterra Indentures to, among other things, eliminate certain of the covenants, restrictive provisions and events of default and modify or amend certain other provisions, including unconditionally releasing and discharging the guarantees by each of Viterra and Viterra B.V. (with respect to the corresponding Existing Viterra Indenture for that series and, together, as the context requires, the "Proposed Amendments"). Supplemental indentures to the Existing Viterra Indentures were executed on September 23, 2024 in order to effect the Proposed Amendments (each an "Existing Viterra Supplemental Indenture" and collectively, the "Existing Viterra Supplemental Indentures"). The Existing Viterra Supplemental Indentures will become operative only upon the settlement date for the Exchange Offers and the Consent Solicitations, which is expected to be within two business days after the Expiration Date.
Each Exchange Offer and Consent Solicitation is subject to the satisfaction of certain conditions, including among other things, the consummation of Bunge's pending acquisition (the "Business Combination") of Viterra. The parties' obligations to complete the Business Combination are conditioned upon (i) the receipt of antitrust approvals and (ii) certain other customary closing conditions. The consummation of the Business Combination is not subject to the completion of the Exchange Offers or Consent Solicitations or a financing condition.
To the extent the Business Combination is not anticipated to occur on or before the Expiration Date, for any reason, BLFC anticipates further extending the then-anticipated Expiration Date until such time that the Business Combination may be consummated on or before the Expiration Date. BLFC will provide notice of any such extension in advance of the Expiration Date.
The regulatory approval process for the announced Business Combination is continuing to progress. Bunge expects to receive the remaining approvals and close the Business Combination in the next several months.

Reported Earlier: Bunge Extends Exchange Offers And Consent Solicitations Deadline To June 13, 2025, For $1.95B In Viterra Notes Swap And Amendments, As Regulatory Approval Progresses For Pending Viterra Acquisition

Bunge Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) shares traded on Thursday. The company along with Repsol (OTC:<a class="ticker" href="https://www.benzinga.com/stock/REPYY#OTC">REPYY</a>) disclosed a significant advancement in<a href="https://www.benzinga.com/pressreleases/25/04/b44973275/repsol-and-bunge-to-boost-development-of-renewable-fuels-in-europe-with-intermediate-crops" target="_blank" rel="noreferrer noopener"> Europe&#8217;s renewable energy sector</a>.
The company introduced camelina and safflower, classified as intermediate novel crops, into the renewable fuel production process. 
These crops will be converted into low-carbon oils, which will then be used to create hydrotreated vegetable oil (HVO) and sustainable aviation fuel (SAF), offering an emissions reduction of up to 90% compared to conventional diesel.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43495895/agribusiness-bunges-q2-earnings-miss-estimates-warns-geopolitical-uncertainty" target="_blank" rel="noreferrer noopener">Agribusiness Company Bunge Misses Q2 Earnings Estimates, Warns Of Geopolitical Uncertainty</a>
This initiative expands the range of sustainable feedstock options available and supports the development of low-emission fuels.
Repsol plans to use its cutting-edge industrial facilities in Spain to process these oils, paving the way for new, sustainable fuel production pathways in the region.
Julio Garros, Co-President, Agribusiness at Bunge said, &#8221;Through industry collaborations, we are adding new oil sources to our global supply chains and investing in processing plants with greater ability to handle and process these crops, expanding our offerings of cost-effective, sustainable feedstocks to customers worldwide,&#8221;
Notably, Repsol and Bunge has earlier committed to advancing research and development efforts to expand the availability of low-carbon feedstocks.
This includes working closely with Spanish farmers to cultivate novel seed varieties, further enhancing the supply chain for advanced renewable fuels.
In April, Bunge said it has entered into definitive agreements to sell its North America dry corn and corn masa milling businesses to&nbsp;Grain Craft,&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44819294/whats-going-on-with-bunge-stock-on-tuesday" rel="noreferrer noopener">an independent flour miller in the U.S</a>.
Investors can gain exposure to the stock via&nbsp;Cohen &amp; Steers ETF Trust Cohen &amp; Steers Natural Resources Active ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSNR#NYSE">CSNR</a>) and First Trust Cons. Staples AlphaDEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXG#NYSE">FXG</a>).
Price Action: BG shares are up 0.96% at $80.59 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44217379/china-hits-soybeans-with-tariffs-its-largest-us-import-along-with-other-agri-products-here-a-list-of-stocks-and-etfs-that-could-be-impacted" target="_blank" rel="noreferrer noopener">China Hits Its Largest US Import, Soybeans, With Tariffs Along With Other Agricultural Products: Here&#8217;s A List Of Stocks, ETFs That Could Be Impacted</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Large Cap

CSNR

Bunge, Repsol Launch Next-Gen Biofuel Initiative In Europe, Target 90% Emissions Cut

Repsol And Bunge Incorporated Intermediate Novel Crops In The Production Of Renewable Fuels. Camelina And Safflower Will Be Processed Into Low-Carbon Intensity Oils And Used As Feedstock To Produce Hydrotreated Vegetable Oil, A Fully Compatible Drop-in Replacement For Conventional Diesel Fuel, Or Sustainable Aviation Fuel For The Decarbonization Of Air Travel.

Bunge Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) shares are trading down<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> Tuesday.</a>
The company said it has entered into definitive agreements to sell its North America dry corn and corn masa milling businesses to Grain Craft, <a href="https://www.benzinga.com/pressreleases/25/04/b44810347/bunge-announces-sale-of-its-north-america-corn-milling-business" target="_blank" rel="noreferrer noopener">an independent flour miller in the U.S.</a>
This transaction includes Bunge facilities in Danville, Illinois; Worthington, Indiana; Crete, Nebraska; Red Oak, Iowa; Muleshoe, Texas; Atchison, Kansas and Queretaro, Mexico.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44811593/bank-of-america-ceo-says-consumer-continues-to-spend-and-maintain-healthy-credit-quality-sticks-to-annual-outlook" rel="noreferrer noopener">Bank of America CEO Says Consumer Continues To Spend And Maintain Healthy Credit Quality, Sticks To Annual Outlook</a>
Bunge Co-President of Agribusiness Julio Garros said, &#8220;We carefully considered how this regional business fits with our long-term plans and made the strategic decision to focus on other areas of our core business that are more strongly connected to our global value chains.&#8221; 
Terms of the deal were not disclosed, and the company said that the completion of the sale is subject to regulatory approval and customary closing conditions.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BG stock has lost over 25% in the past year. Investors can gain exposure to the stock via&nbsp;AdvisorShares Focused Equity ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWS#NYSE">CWS</a>) and&nbsp;Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GABF#NYSE">GABF</a>).
Bunge held $3.31 billion in cash and equivalents<a href="https://www.benzinga.com/pressreleases/25/02/b43489190/bunge-reports-fourth-quarter-and-full-year-2024-results" target="_blank" rel="noreferrer noopener"> as of Dec. 31, 2024.</a>
In a press release dated Feb. 5, the company said its long-term debt was $4.694 billion.
&#8220;In Milling, full-year results are expected to be up from last year,&#8221; Bunge had said on Feb. 5.
BG Price Action: Bunge Global shares are trading down 1.61% to $75.84 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800514/these-gaming-stocks-are-under-pressure-as-analyst-cuts-forecast-on-macau-risk-and-soft-vegas-data" target="_blank" rel="noreferrer noopener">These Gaming Stocks Are Under Pressure As Analyst Cuts Forecast On Macau Risk And Soft Vegas Data</a></li>
</ul>
Photo: Zoran Zeremski via Shutterstock

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GABF

What's Going On With Bunge Stock On Tuesday?

During the last three months, 5 analysts shared their evaluations of Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $83.6, a high estimate of $95.00, and a low estimate of $74.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.1%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744725642_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Bunge Global's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Thomas Palmer &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $77.00&#x7C;$76.00 &#x7C; 
&#x7C;Vincent Andrews &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $74.00&#x7C;$90.00 &#x7C; 
&#x7C;Steve Byrne &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $87.00&#x7C;$105.00 &#x7C; 
&#x7C;Benjamin Theurer &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $85.00&#x7C;$95.00 &#x7C; 
&#x7C;Benjamin Theurer &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $95.00&#x7C;$115.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bunge Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bunge Global compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bunge Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bunge Global's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bunge Global analyst ratings.</a>
<h2>Delving into Bunge Global's Background</h2>
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
<h3>Key Indicators: Bunge Global's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Bunge Global's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -9.33%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Bunge Global's net margin is impressive, surpassing industry averages. With a net margin of 4.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bunge Global's ROE stands out, surpassing industry averages. With an impressive ROE of 6.01%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bunge Global's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.4%, the company showcases efficient use of assets and strong financial health.
Debt Management: Bunge Global's debt-to-equity ratio stands notably higher than the industry average, reaching 0.72. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Bunge Global

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL